7th Jul 2025 11:42
Haleon PLC - Surrey, England-based consumer healthcare products - Provides a historical earnings breakdown based its new reporting structure ahead of interim results on July 31. Haleon at a capital markets day back in May said it would start to report in six product categories: Oral Health, Vitamins, Minerals & Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health & Other. This splits out Respiratory Health and Therapeutic Skin Health & Other from what had been Digestive Health & Other. Within Haleon's GBP11.23 billion in total revenue in 2024, Oral Health, which includes the Sensodyne brand, was the biggest of these segments at GBP3.31 billion, followed by Pain Relief, with the Advil and Panadol brands, at GBP2.56 billion. Haleon says its geographic split remain unchanged.
Current stock price: 376.70 pence, down 0.3% on Monday morning in London
12-month change: up 15%
By Tom Waite, Alliance News editor
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Haleon